Mutations prevent programmed cell death
The scientists started analyzing samples of human mantle cell lymphoma in a bid to find errors in the DNA. They discovered a region that is mutated in almost 30 percent of patients…
The scientists started analyzing samples of human mantle cell lymphoma in a bid to find errors in the DNA. They discovered a region that is mutated in almost 30 percent of patients…
Although scientists have known for about twenty years about double minutes, little chromosomal fragments which sometimes appear during cellular division, they have just started to understand their exact function. Due to replication errors, these mini-chromosomes lack centromere, which allows them to replicate extremely rapidly and autonomously. Scientists therefore suspect that they play a role in the development of cancers, diseases that are caused by mutations in genes that control cellular metabolism and development…
Triple negative breast cancers (TNBCs) have a high mortality rate owing to aggressive proliferation and metastasis and a lack of effective therapeutic options. However, Professor Auguste’s team, discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) in human TNBC cell lines and tissues, and demonstrated that it is a potential molecular target and biomarker for TNBC therapy and diagnosis. “No therapies are available to treat triple negative breast cancer cells and because of that patients have a poor prognosis,” said Professor Auguste, the recipient of a 2014 Presidential Early Career Award for Scientists and Engineers. The Identification of ICAM-1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care, she added. …
Delivering cancer drugs directly to tumors is difficult. Scientists are working on new approaches to overcome the natural limitations of drugs, including loading them into nanoparticles. “The drug is packaged into a lipid ball significantly smaller than the width of a hair to make it soluble in the blood stream and prevent negative side effects. The drug-containing nanoparticle ball then travels in the bloodstream to the tumor, where it accumulates and the drug is released in the tumor to kill the cancer cells,” said Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery and director of the Penn State Hershey Melanoma Center. …
Scientists at Brigham Young University discovered the two proteins that pair up and switch on this process — known as autophagy. …
“Scientists have long observed that human and mouse cancers contain a lot of nerves in and around the tumor cells,” said Dr. …
source : http://www.sciencedaily.com/releases/2014/05/140521175922.htm
source : http://www.sciencedaily.com/releases/2014/05/140507100434.htm
source : http://www.sciencedaily.com/releases/2014/04/140422130851.htm
source : http://www.sciencedaily.com/releases/2014/03/140305125144.htm